Arsanilic acid (reagent grade) for injection into mice was dissolved in the minimum quantity of 0. I N NaOH, the pH of the solution adjusted to 7.0 and the solution was Seitz filtered. Colchicine u.s.P, was dissolved in water and Seitz filtered, each day immediately before use. human plasma and thrombin, the dotting process was markedly inhibited. Inhibition occurred, too, when fibrinogen alone was used, and indeed here the pattern of inhibition showed particular quantitative relationships. Figs. I and 2 show that, in different experiments, the speed of clotting in systems containing these azoproteins bears a constant relationship to that in the controls using thrombin concentrations from 1.0 to 10.0 units/ml. In other experiments (Figs. 3 and 4) the delay in dotting time was directly proportional to the concentration of azoprotein, above the lowest concentrations (0.025 mg/ml or less). The kinetic relationships are typical of those produced by reversible inhibitors of enzymic reactions (2) , but on account of the complexity and the number of different reactions involved in the clotting of fibrinogen, as will be described, they do not provide decisive information on the exact inhibitory mechanism. These experiments however immediately made one point clear, namely that the mechanism of inhibition differs greatly from that caused by heparin. For with the purified fibrinogen used in these experiments, heparin, which requires a plasma cofactor for its activity (3), was almost completely devoid of effect, even at a concentration (0.1 mg/ml) which produces complete incoagulability of plasma.
RESULTS

Effects of Azoproteins on the Clotting of Fibrinogen by
When other analogues of 4-arsonophenylazoproteins were tested for their effects on the clotting of fibrinogen by thrombin, they produced results similar to those obtained with recalcified plasma. Anticoagulant activity was confined to the acidic azoproteins (Table I) . Again the anticoagulant activity of 4-arsonophenylazoalbumins increased with their arsenic content, up to approximately 6.5 per cent (Table II) , while in other experiments substances containing 11 and 17 per cent As were markedly less effective. Azoalbumins were more active than azoglobulins of comparable arsenic content, but the 4-arsonophenylazo derivatives of amino acids and of polypeptides had no anticoagulant activity. Similarly two 4-arsonophenyl derivatives of bovine albumin which did not contain azo linkages were ineffective.
The Mechanism of Inhibition of the Throrabin-Induced Clotting of Fibrinogen by Acidic
Azoproteins.--In recent years the final stages in the clotting process have been studied by a number of workers (see reviews of Scheraga and Laskowski, reference 4, and B16mback, reference 5). It has been found that the appear-ance of a clot in mixtures of fibrinogen and thrombin is preceded by three distinct stages. In the first, thombin acts enzymicaUy on fibrinogen to liberate 2 distinct peptides and carbohydrate substances of less well defined composition, converting the fibrinogen molecule into a monomer of fibrin. In the second stage monomers condense to form short polymers of varying size. In the third stage, Solutions made in 0.15 ~ NaC1 and pH adjusted to 7.0 with 0.15 ,~ NaOh.
the intermediate polymers combine in a highly organized manner to form strands of insoluble fibrin. Theoretically, the acidic azoproteins might inhibit the clotting of fibrinogenthrombin mixtures by acting on any of the three stages which have been described.
Acidic azoproteins produced no demonstrable destruction of thrombin itself (see Figs. 1 to 4) , Prior incubation of azoprotein with thrombin (for example, in one experiment incubating 1 ml of a solution containing 0.5 mg of 4-arsonophenylazoprotein and 10 units thrombin at 37°C for 30 minutes) failed to cause any greater anticoagulant effect than when azoprotein came in contact with thromin only at the beginning of the clotting process. Similarly, virtually no inhibitory effect was produced on the hydrolytic action of thrombin on tosyl arginine methyl ester (6) . For example, in incubation mixtures, hydrolysis produced by 5 units/rnl of thrombin on 0.01 ~s tosyl arginine methyl ester solution proceeded at 86 to 99 per cent of the control rate in the presence of concentrations of 4-arsono-, 4-sulfono-, and 4-carboxyphenylazoalbumin of 8.0 mg/ml. In comparable experiments these concentrations of azoprotein caused complete inhibition of the clotting of fibrinogen. Further experiments soon showed that the inhibitory action of acidic azoproteins was brought about by reaction with the fibrinogen itself.
Reaction of Acidic Azoproteins with Fibrinogen.--It was observed that when 4-arsonophenylazoprotein was added to slightly acidified human plasma, a colored precipitate formed. No such change occurred when serum was used. When the phenomenon was examined in further detail (Table III) it was seen that 4-arsonophenylazoalbumin and also 4-carboxyphenylazoalbumin brought about the formation of a precipitate when mixed with plasma at pH 6.1.4-Sulionophenylazoprotein caused precipitation at even higher pH, a distinct turbidity was observed at pH 6.7, and the quantity of precipitate reached its maximum at pH 6.3. In each case, the precipitate redissolved on restoring the pH to neutrality. With stronger acidification, to pH values of 5.2 and below, plasma alone became turbid, but at these pH values scarcely any change was produced on the addition of azoprotein.
In keeping with their lack of anticoagulant properties, azoproteins without an acidic group caused no precipitation, and neither did 4-arsonophenylazo derivatives of peptones or amino acids. In other experiments 4-arsonophenylcarbamoylmethylalbumins and 4-arsonophenyltriazinylalbumins, substances which lacked an azo group, failed to cause precipitation despite their content of arsonic groups.
Numerous experiments showed that the precipitate formed from plasma was in fact a complex of azoprotein and fibrinogen, for (a) serum showed no precipitation in the presence of the acidic azoproteins under identical conditions to those shown with plasma, till pH values below 5.2 were reached; (b) plasma, from which fibrinogen was removed by ~ saturation with sodium chloride or 1/~ saturation with ammonium sulfate, followed by dialysis against 0.15 M sodium chloride, failed to produce any precipitate on the addition of azoprotein at pH values above 5.2, whereas the fibrinogen-containing fraction similarly treated was immediately precipitated by azoprotein at pH 6.3; and (c) when the precipitate formed from the mixture of acidified plasma and azoprotein was separated and dissolved in 0.15 M NaCI at pH 7.0, high concentrations of thrombin (i50 units/ml) brought about coagulation, although, instead of the usual gelatinous clot a lumpy precipitate was slowly formed.
Highly purified preparations of fibrinogen readily formed a precipitate with acidic azoproteins, and indeed at a higher pH than was observed with plasma. For example, a preparation of bovine fibrinogen, (protein 90 per cent coagulable by thrombin) was dissolved (1.5 mg/ml) in 0.14 ~ NaC1-0.01 ~r sodium phosphate buffer at pH 7.7. When either 4-arsono-, 4-sulfono-, or 4-carboxyphenylazoalbumins were added at concentrations of 0.1 mg/ml, cloudiness which led to heavy precipitation developed after 2 hours at room temperature. In the absence of azoproteins the fibrinogen showed no instability under these conditions. A similarly delayed precipitation occurred at pH 7.2, but below this, at pH 6.5 a heavy precipitation immediately formed.
It is clear from these experiments that acidic azoproteins form particularly strong complexes with fibrinogen. The formation of insoluble azoprotein-protein complexes in the interisoelectric regions, that is, at pH values between the isoelectric points of the azoprotein and the protein under test has been shown previously by Horowitz et al. (7) . But as the isoelectric point of fibrinogen is pH 5.5 (8) and that of the acidic azoalbumins less than 4.4 (9, 10) the complex formation now demonstrated plainly occurs under quite different conditions. Indeed considerably less precipitation occurs in the interisoelectric region than at higher pH values.
These results then showed that the inhibitory action of azoproteins on the thrombin induced clotting process could be explained by the formation of an azoprotein-fibrinogen complex, producing a substrate resistant to the enzymic action of thrombin. Confirmatory evidence for this explanation was obtained by measuring the anticoagulant effectiveness of acidic phenylazoproteins at different pH values.
Effects of Changes in pH on the Anticoagulant E~rectivencss of Acidic Azopro-
teins.--It has been shown that the binding of fibrinogen to acidic azoproteins becomes stronger at pH values decreasing from neutrality. If, therefore, the anticoagulant action is due to such a combination then it, too, should increase under similar conditions. The results shown in Table IV bear this out, for although a change in pH from 7.0 to 6.4 did not alter the clotting times induced by thrombin in control plasma samples, the anticoagulant effectiveness of the 3 acidic azoproteins increased markedly. Conversely, increasing the pH from 7.1 to 8.0, which again had no effect on the clotting time of controls, resulted in a marked decrease in anticoagulant activity. Comparable results were obtained using purified bovine fibrinogen and thrombin mixtures at different pH values. These results, however, did not exclude the possibility that acidic azoproteins might also act on the polymerization processes. This possibility was examined directly.
Effects of Azoproteins and Related Substances on the Pol3mwrization of Fibrin.-
The experiments of Waugh and coworkers (11) (12) (13) have shown that under conditions similar to those occurring in vivo the enzymic action of thrombin on fibrinogen is the rate limiting step in the clotting of fibrinogen. But under conditions of increased electrolyte concentration or decreased pH the polymerization reactions are markedly inhibited and instead their rate now controls the speed of clot formation (1, 14) . By using such systems the effect of azoproteins on fibrin polymerization may be examined directly, and independently of actions on other stages.
(a) Effects of azoproteins and related substances on systems in which fibrin polymerization is inhibited at acid pH:
The principle of the present experiment depends on the finding of Laki (1) that at pH 5.0 thrombin acts on fibrinogen at a slow rate to produce fibrin monomers, but under such conditions these are unable to polymerize and therefore accumulate. When the pH is raised to 7.0 two changes take place, thrombin begins to act more rapidly, and the accumulated fibrin monomers begin to polymerize. Clot formation results. The speed of clotting plainly depends on both processes, but will be more rapid with increasing initial concentration of fibrin monomers. When the initial concentration of fibrin monomers is sufficiently high the speed of clot formation following the restoration of the pH to neutrality will then come close to being a measurement of polymerization rate.
The results of an experiment performed in this way are shown in Table V . 4-Arsonophenylazoalbumin, in marked contrast to the inhibitory effects shown on other clotting processes, here produced a marked acceleration of clotting in systems containing monomeric fibrin. The accelerating effect became particularly marked in preparations in which fibrinogen-thrombin incubation was prolonged for 16 hours at acid pH. Mter the pH was raised to 6.8, control mixtures clotted in 48 seconds, while in the presence of 4-arsonophenylazoalbumin this time was reduced to 10 seconds. Polymerization of fibrin was also accelerated by 4-sulfono-and 4-carboxy- phenylazoproteins as is shown in Table VI , but 2 non-acidic azoproteins, azopeptones, and 2 azoamino acids failed to show this effect, and indeed, the 2 azoamino acids caused a slight inhibition. There is thus again identity between those azo derivatives which possess an overall anticoagulant activity with those which cause acceleration of fibrin polymerization.
(b) Effects of azoproteins on systems in which fibrin polymerization is inhibited by raised electrolyte concentration:
Acidic azoproteins also promote polymerization of fibrin when this is delayed by high electrolyte concentrations, as may be seen in Fig. 5 . When 4-sulfonophenylazoproteins and 4-carboxyphenylazoproteins were added to thrombin-fibrinogen mixtures their anticoagulant effectiveness became progressively less as the salt concentration was increased. At concentrations from 0.30 ~ KC1 clotting was considerably delayed in the controls, but in these systems the added azoproteins produced a marked reduction in the dotting times.
Low Capadty of Acidic Azoproteins to Combine with Fully Polymerized Fibrin.--When clots obtained from coagulation mixtures containing azoproteins were removed and carefully washed in physiological saline virtually no color remained with them. The indication that acidic azoproteins were not bound to the fibrin clot in substantial amounts was confirmed in a number of other ways. For ex- Table V . Clotting time measured from addition of fibrinogenthrombin to other previously mixed reagents. All procedures at 23°C. ample, in one experiment the optical density (at 390 m/z) of a dotting mixture containing human plasma (final dilution 1/5) and 4-arsonophenylazoalbumin (preparation M9, 0.6 mg/ml final concentration) was measured before clotting had been induced by the addition of strong thrombin preparation, with removal of the clot after clotting was complete. A decrease in optical density of only 7.9 per cent resulted. Plasma itself has a very low optical density relative to azoprotein under the conditions used. Since the optical density of azoproteinplasma mixtures is higher than the sum of their separate optical densities, (presumably due to complex formation with fibrinogen), this figure probably represents even too high an estimate of azoprotein binding to the clot. Similar results were obtained using purified fibrinogen (Pentex Inc., final concentration 0. (1) was dissolved (300 mg per cent) with different amounts of KC1 and azoprotein (AP) to give the concentrations shown. In the control, bovine albumin 3 mg/ml was used. Clotting times were measured from the addition of 0.1 ml thrombin (10 units/ml) to 0.3 ml of fibrinogen containing solutions. Temperature 38°C, pH 7.0. taneous and transplanted tumors have shown the greatly varied patterns of sensitivity of different tumors to chemotherapeutic agents, (see, for instance Sugiura, reference 15). Now, mouse Lymphoma 6C3HED, in contrast to its sensitivity to 4-arsonophenylazoprotein, is resistant to the effects of most agents commonly used in the therapy of human and experimental tumors (16, 17) . However, a number of experiments by Bass and Probert (18) showed that this lymphoma was unusually sensitive to inhibition by colchicine. Complete regression of established, palpable tumors was obtained in a high proportion of treated animals (30 to 100 per cent in different groups). It should be noted that colchicine is in general of very limited effectiveness in the treatment of experimental tumors, (see, for instance, Ludford, reference 19, and Eigsti and Dustin, reference 20). Of many tumor cell lines tested by different workers only one can be considered to have a sensitivity to colchicine even comparable to that of Lymphoma 6C3HED and this, like Lymphoma 6C3HED, originated as a thymic lymphoma induced in a C3H mouse by estrogens (21) . Now, the actions of colchicine and of arsenic on cells of many different kinds, appear remarkably similar on microscopical examination. Both agents powerfully inhibit mitosis. Colchicine, produces arrest of mitosis in metaphase, by destruction of the mitotic spindle, as was first shown by Dustin and his co-workers (22) . Closely similar changes due to arsenic were shown by Piton (23), Dusfin and Gr~goire (24) , and Ludford (25) .
The purpose of the experiments now to be described was to determine whether the inhibitory action of both 4-arsonophenylazoproteins and colchicine on Lymphoma 6C3HED could be correlated with similar degrees of activity on the mitotic process.
Actions of 4-Arsonopkenylazoprotein, Arsanilic Acid, and Colchiclne on Cells of Lymphoma 6C3HED and on Their Mitosis.--Preliminary microscopical examination of sections of a number of 6C3HED lymphomas treated with 4-
arsonophenylazoprotein showed that before necrosis occurred, mitotic figures became particularly numerous (17) . These actions of 4-arsonophenylazoprotein were investigated in more detail, and compared with those brought about by other agents.
Groups of ZBC mice (19 to 23 gin) were implanted with 500,000 6C3HED cells subcutaneously in each flank. In 11 days tumors 1.0 to 1.5 cm across formed at each implantation site. Treatment of the tumor bearing mice by 3 daily intraperitoneal injections of 4-arsonophenylazoprotein, colchicine, or arsanilic acid in doses indicated in the text, was then begun. Two treated mice were sacrificed each day. In these, tumors were removed and carefully separated from the abdominal musculature, slices of the tumors were then cut vertically through the longest axis, preserving the deep surface. On each day the 4 separate tumor samples obtained were fixed in Zenker's solution or neutral formalin. Sections of each tumor were stained with hematoxylin and eosin and by Feulgen's method. The remaining tumor tissue was removed and pressed through a metal mesh into a quantity of Ringer's solution containing 20 gm bovine albumin (Armour Pharmaceutical Company fraction IV) at pH 7.2, to yield a suspension of free cells which was lightly centrifuged and smear preparations made from the sediment. These were air-dried, fixed in absolute methanol and stained with May-Grunewald-Giemsa and by Feulgen's method.
Mitotic counts were performed on tumor tissue sections in their most highly vascularized and actively growing parts, that is, in tissue immediately adjacent to the abdominal musculature. In all cases mitoses became less frequent in the center of the tumor. In each tumor the number of mitoses in 2000 cells was counted.
Smear preparations gave mitotic counts considerably lower than were obtained from the sections, the reason for this lying most probably in the selection of cells which occurs in preparing the suspensions, the central cells with a low mitotic rate presumably being pressed through the mesh more readily than beginning treatment; of these 89 per cent were metaphase forms. At this time the tumors had decreased markedly in size but on microscopic examination they appeared as discrete white plaques, which showed none of the hemorrhagic change found by others in less sensitive tumors treated with colchicine (19) . The lymphomas showed considerable cell damage, many cells were swollen, eosinophilic and had lost their normally observable detailed structure, many of the nuclei were pyknotic and others were undergoing fragmentation. The microscopic changes and the apparent .absence of vascular damage closely resembled the findings of Strong eta/. in the treatment of their colchicine-sensifive C3H lymphoma (21) . On the 4th day, however, with cessation of treatment, the number of mitotic forms was considerably less, cell damage was still observable but less prominently. Subsequently the appearances rapidly returned to control levels. Failure to bring about complete regression was probably related to the relatively large size of the tumors and to the short duration of treatment, for, in another experiment in which treatment was begun on the 
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FIo. 8. Mitotic counts on 6C3HED tumors in ZBC mice treated with arsanilic acid. Resuits A and B were obtained from separate experiments, counts being performed in each as described in Fig. 6 . Arsunilic acid dissolved in 0.1 N NaOH and pH adjusted to 7.0 was used for treatment. 6th day after implantation, lymphomas were completely supressed in 2 of 3 mice given 5 daily injections of 0.020 mg colchicine per day, and in 3 of 3 mice when a dosage of 0.025 mg was given. No obvious general toxicity was produced by these doses.
(c) Arsanilic acid: Arsanilic acid administered in a dosage of 1.5 mg per day (0.5 mg As) produced no significant rise in the number of mitoses in the tumor. 3.0 rag/day produced marked toxicity in the recipient animals and for this reason it was only possible to administer 2 doses. Even at this level of treatment the effect on mitosis was slight. The proportion of mitotic figures reached 5.4 per cent as a maximum and decreased within 48 hours of ending treatment, to the same level as in untreated controls.
(d) 4-Arsonophenylagoallrumin:
The effect of 4-arsonophenylazoalbumin on Lymphoma 6C3HED was considerably different from that produced by other agents. In Fig. 9 it will be seen that 24 hours after beginning treatment, the azoprotein had produced a moderate increase in the number of mitoses and particularly in the proportion of metaphase forms. On succeeding days the number of mitoses increased gradually, reaching 4.2 per cent by the 4th day. But, after this time the porportion of cells in mitosis increased strikingly, on the 5th day to 10.1 per cent, of which 90 per cent were metaphase forms; on the 6th day it reached 21.0 per cent. By this time there was marked cell destruction and indeed, while it was possible to examine sections from 4 experimental animals on each of the previous days, by the 6th day 2 of the animals showed tumors in such advanced necrosis that mitotic counts could not be performed on them. It should be noted that this mitotic crisis and tumor necrosis occurred 3 days after treatment ended, in marked contrast to the findings with colchicine and arsanilic acid, in which the number of mitoses rapidly decreased after treatment was ended.
Abnormal mitotic forms were found in all the smear preparations of Lymphoma 6C3HED which were examined, including those from untreated controls, but they became considerably more numerous in animals treated with colchicine or 4-arsonophenylazoprotein. The changes of C-mitosis, which are associated with spindle damage (26) , were produced by both substances. The "ball-metaphase" with the appearances of chromosomal adhesion and loss of orientation was particularly commonly seen, as were multipolar mitoses, "lagging" chromosomes and anaphase bridging.
Although colchicine and presumably 4-arsonophenylazoproteins too, inhibit cell processes other than mitosis, the close parallel observed microscopically between the 2 processes provides considerable evidence that metaphase arrest may in fact be a major cause of tumor cell destruction. Furthermore, daily examination of tumor size in similarly treated animals which were not used for histological preparations showed that reduction in tumor size follbwed closely the periods of maximal mitotic arrest. There was no evidence of any other reaction produced on the tumors by co!chicine or 4-arsonophenylazoprotein, and particularly no evidence of vascular damage to the tumors. In both cases the regressing tumors were converted into pale bloodless plaques, tumors and other tissues too, in animals treated with 4-arsonophenylazoprotein acquiring its yellow color.
DISCUSSION
In this and an associated paper certain properties exhibited by 4-arsonophenylazoproteins as anticoagulants and as antilymphoma agents are described, and the possibility is considered that the anticoagulant and antilymphoma effects may come about through related means.
As anticoagulants the 4-arsonophenylazoproteins present a number of striking features. The experiments now described show that these substances form part of a larger group of previously unrecognized anticoagulants, the acidic azoproteins. Strict structural requirements determine their anticoagulant effectiveness: the possession of free acidic groups and their attachment through azo linkages to protein molecules. When chemically related substances which did not possess each of these characteristics were examined they were found to be devoid of anticoagulant activity.
A number of negatively charged macromolecular substances resemble the acidic azoproteins in being anticoagulants. Dextran sulfate, polyanethol sulfate, and most notably heparin are all members of this class. It is significant, however, that while these and previously reported macromolecular substances are dependent for anticoagulant activity on the sulfonic groups they contain, azoproteins having not only this group but 2 others, namely carboxylic and arsonlc groups, are also highly effective anticoagulants.
How do the acidic azoproteins bring about their anticoagulant effect? As is the case with other anticoagulants their actions are complex. It has here been shown that the final stages of clot formation, namely the conversion of fibrinogen to fibrin, form an important site of the inhibition. A number of other experiments, which are not reported here since they do not appear relevant to an understanding of the antilymphoma activity of some of these substances, show that the acidic azoproteins produce additional inhibitory effects on other stages of coagulation, particularly on thromboplastin generation.
Evidence has now been presented to show that acidic azoproteins inhibit the clotting of fibrinogen through formation of a fibrinogen-azoprotein complex which is resistant to the enzymic action of thrombin. Also that azoproteins react with polymerizing fibrin, the reaction leading uniquely to an acceleration of this process. Acidic azoproteins are much more reactive with fibrinogen and fibrin monomers than with fully formed fibrin, for after polymerization very little azoprotein remains with the clot.
Earlier workers have shown that fibrinogen can form complexes with several macromolecular substances which carry a strong negative charge. Such complexes are formed with polyanethol sulfate and under some conditions with heparin and other carbohydrate polysulfruic acid esters (27) (28) (29) . No effect of these or similar substances on the fibrin polymerization reactions has however been reported. It is notable that while many substances inhibit the polymerization reactions (30) , acidic azoproteins are the first substances to be clearly shown to accelerate these stages.
The accelerating effect of acidic azoproteins on fibrin polymerization can be explained by reaction between the acidic groups of the azoprotein and the free basic groups (31) of fibrin subunits. If each molecule of azoprotein complexes with several molecules of unpolymerized or partially polymerized fibrin, these would be brought into close proximity and might then more rapidly undergo further polymerization. When polymerization is complete it appears that few sites remain in the fibrin at which combination with azoprotein can occur, for only very small amounts of azoprotein are found in the final clot.
4-Arsonophenylazoproteins strongly inhibit the growth of Lymphoma 6C3HED in vivo while other related arsenic-containing substances which lack anticoagulant activity produce no antilymphoma effects. Lymphoma 6C3HED is insensitive to most substances ordinarily used in the treatment of human and animal tumors, but it is highly sensitive to colchicine (16--18) . Both 4-arsonophenylazoproteins and colchicine cause a powerful metaphase arrest in 6C3HED cells in vivo, as has now been shown, and in a wide variety of different cell types arsenicals and colchicine are known to produce this effect by inhibiting contraction of the mitotic spindle (22) (23) (24) (25) .
Inou~, in work on the mitotic apparatus of various animal and plant cells in vivo, has shown the transformation of the spindle in metaphase from a sol in which the molecules occupy a random arrangement to a fibrous structure in which they are arranged in a precise longitudinal pattern (32) . Mazia, who isolated the mitotic apparatus of sea urchin eggs, has shown that polymerization of the spindle protein is greatly dependent on the balance of --S--S--and --SH groups (33) . While undoubtedly bonds of various other kinds are formed, hydrogen bonds between --SH groups of adjacent molecules are particularly important, these being in equilibrium witha relatively small number of intermolecular --S--S--linkages (34) . Trivalent arsenic, in combination with --SH groups clearly might inhibit polymerization of the spindle protein.
Do the structural characters of 4-arsonophenylazoprotein that determine its ability to form complexes with fibrinogen and fibrin monomers also determine its ability to arrest mitosis in proliferating Lymphoma 6C3HED cells? The studies of Heilbrunn and other workers (see Heilbrunn, reference 35) have demonstrated many striking similarities between processes occuring in blood coagulation and those involved in the formation and contraction of the mitotic spindle. These similarities have again been reviewed by jensen (36) . From the present findings, however, it is clear that the anticoagulant effect of 4-arsonophenylazoprotein is not in itself responsible for lymphoma inhibition; for acidic azoproteins other than those containing arsenic are strong anticoagulants, yet these fail to inhibit tumor growth significantly, and they fail also to arrest the process of mitosis in proliferating Lymphoma 6C3HED cells in viva, as microscopic studies have shown. The essential part played by arsenic in conferring antilymphoma properties on the azoproteins with which it is combined is further shown by the ability of dimercaprol to interfere with the antilymphoma effects of 4-arsonophenylazoprotein.
From the evidence now presented, the anticoagulant and tumor inhibitory effects of 4-arsonophenylazoproteins may be related in the following way. Since 4-arsonophenylazoproteins can combine particularly strongly and with considerable specificity with fibrinogen and polymerizing fibrin, it may be postulated that in cells of Lymphoma 6C3HED the azoprotein combines in a similar way with unpolymerized and polymerizing proteins of the mitotic spindle. Furthermore, it should be noted that, under such circumstances, a high concentration of arsenic might be brought to sites dependent for functional activity on their sulfhydryl groups.
But can a molecule the size of 4-arsonophenylazoprotein enter tumor cells? McMaster and Kruse have elegantly demonstrated the ability of azoproteins not only to enter macrophages but also to persist there for long periods (37) . Like macrophages, cells of Lymphoma 6C3HED are actively phagocytic, ingesting erythrocytes, nucleated cells and various cell particles (38, 39) . Furthermore 6C3HED cells have been shown to accumulate C1Mabeled serum albumin in vivo (40) ; and it ~as recently been shown that injected 4-arsono-phenylazoproteins are taken up by tumors of a transplantable mouse ependymorea in vivo, though in this case in a smaller amount than by the liver or other organs (4l).
Can reduction of pentavalent arsenic in 4-arsonophenylazoalbumin to the trivalent form take place in vivo, thus enabling reaction of arsenic with --SH groups to occur? Again this seems probable. Voegtlin and Smith have shown that pentavalent arsenicals undergo reduction in vivo before exerting their trypanocidal effects (42) . It has also been shown that such activation can occur even by incubation of pentavalent arsenicals with blood in vitro (43) .
Would 4-arsonophenylazoproteins be likely to form complexes with protein of the mitotic spindle? Fibrinogen and other natural fibrous proteins have many structural features in common, as has been brilliantly shown by Astbury and others (see for instance, reference 44). Fibrinogen has a molecular weight of approximately 330,000, and like other members of this group is a highly asymmetrical molecule (4) . Much less information is available about proteins constituting the mitotic spindle. Kane and Hersh using extracts of the soluble proteins from sea urchin eggs showed these to contain considerable amounts of a protein which gelled in the presence of calcium and which was both highly asymmetrical and of similar molecular weight to fibrinogen. After fertilization and corresponding with spindle formation the protein greatly decreased in amount (45) . Although this protein, perhaps a spindle precursor, is immunologically different from proteins extracted directly from the mitotic apparatus (46), Mazia (47) and Zimmerman (48) have shown that the mitotic apparatus consists predominately of a single protein that is solubilized by --SH reagents and has a molecular weight virtually identical with that obtained by Kane and Hersh. From the findings as a whole it can be seen that the hypothesis here presented is consistent with what has been learnt thus far about the processes of clotting and mitosis, and consistent too with the observations made thus far on the anticoagulant and antilymphoma effects of 4-arsonophenylazoprotein.
SU'M'~AR¥
Experiments here given show that 4-arsonophenylazoproteins form complexes with fibrinogen which are resistant to the enzymic action of thrombin, coagulation being thus inhibited; also that arsenic dzoproteins combine strongly with polymerizing fibrin, the reaction leading uniquely to acceleration of the process. Ordinary arsenicals have little or no effect on the proliferation of Lymphoma 6C3HED cells in vivo. 4-Arsonophenylazoproteins, by contrast, are strongly inhibitory, and they arrest the process of mitosis in metaphase, as does colchicine.
Considered together with the observations of the preceding paper, the findings suggest that 4-arsonophenylazoproteins may exert their anticoagulant and anfilymphoma effects by similar or related means: in the former instance, by combining in vitro with fibrinogen and polymerizing fibrin, thus altering the clotting process as mentioned above; and in the latter instance by combining, perhaps in a similar way, with polymerizing proteins in the mitotic spindle of proliferating Lymphoma 6C3HED cells, thus arresting mitosis.
Further implications of the findings are discussed.
